Allurion Technologies Inc (ALUR) stock saw a modest uptick, ending the day at $8.69 which represents a slight increase of $4.99 or 134.86% from the prior close of $3.7. The stock opened at $16.79 and touched a low of $7.

In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of effect on lean mass.

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 29.90% of Allurion Technologies Inc (ALUR)’s shares, while financial institutions hold 21.21%.

Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost. 1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining,